Immunopathogenesis and treatment of cytokine storm in COVID-19

Area of Science:

• Immunology
• Virology
• Critical Care Medicine

Background:

• Severe COVID-19 involves systemic hyper-inflammation and organ failure, often driven by a 'cytokine storm'—an excessive immune response.
• The exact pathogenesis of COVID-19 cytokine storm remains unclear, though impaired type-1 interferon (IFN) responses and elevated cytokines like IL-6 and IL-1 are implicated.
• Anti-inflammatory therapies are crucial for severe COVID-19, with cytokine-targeted drugs showing promise, but specific treatment guidelines are lacking.

Purpose of the Study:

• To provide an overview of the cytokine storm in COVID-19.
• To review current and emerging treatments for COVID-19-associated cytokine storm.
• To discuss the potential of extracorporeal cytokine removal as a therapeutic strategy.

Main Methods:

• Literature review of studies on COVID-19 cytokine storm pathogenesis.
• Analysis of clinical evidence for anti-inflammatory therapies, including cytokine-targeted drugs (e.g., tocilizumab, anakinra, baricitinib).
• Exploration of extracorporeal cytokine removal techniques.

Main Results:

• Impaired type-1 IFN response in early COVID-19 infection is a key factor in cytokine storm development.
• Cytokines such as IL-6 and IL-1 play significant roles in severe COVID-19.
• Existing treatments include cytokine-targeted therapies, but optimal patient selection and timing remain undetermined.
• Extracorporeal cytokine removal presents a potential therapeutic avenue.

Conclusions:

• Understanding the cytokine storm's pathogenesis is critical for effective COVID-19 treatment.
• Cytokine-targeted therapies and potentially extracorporeal cytokine removal offer new hope for managing severe COVID-19.
• Further research is needed to establish clear guidelines for anti-inflammatory treatment selection and application.